American Journal of Clinical Dermatology

, Volume 15, Issue 5, pp 425–444 | Cite as

Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management

Review Article

Abstract

Targeted therapies have developed rapidly over the last few years in the field of oncology thanks to a better understanding of carcinogenesis. They target pathways involved in signal transduction (EGFR, HER2, HER3, HER4, FLT3, RAS, RAF, MEK, KIT, RET, mTOR, SRC, EPH, SCF), tumor angiogenesis (VEGFR, TIE2), and tumor microenvironment (PDGFR, FGFR). They rarely cause the systemic adverse reactions generally associated with chemotherapy, but frequently cause disabling and specific skin toxicity. The impact on patient quality of life can be important both in terms of symptoms caused and of potentially aesthetic consequences. Inappropriate management can increase the risk of dose reduction or discontinuation of the cancer treatment. In this review, we will discuss skin toxicity associated with the main drug classes—EGFR, BRAF, MEK, mTOR, c-KIT, CTLA4, and SMO inhibitors, and anti-angiogenic agents. Targeted therapy-induced skin toxicities will be detailed in terms of symptoms, frequency, evolution, complications, and topical and oral treatments in order to improve their diagnosis and management.

References

  1. 1.
    Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong FA, Lavrijsen AP, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev. 2012;38(5):505–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges. 2011;9(3):195–203.PubMedGoogle Scholar
  3. 3.
    Robert C, Sibaud V, Mateus C, Cherpelis BS. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol. 2012;39(2):227–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–95.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2010;22(3):524–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouche O, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist. 2012;17(4):555–68.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010;15(9):1016–22.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34):5390–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol. 2009;61(4):614–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Reguiai Z, Bachet JB, Bachmeyer C, Peuvrel L, Beylot-Barry M, Bezier M, et al. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Support Care Cancer. 2012;20(7):1395–404.PubMedCrossRefGoogle Scholar
  14. 14.
    Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, et al. Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res. 2013;5:401–8.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009;115(6):1286–99.PubMedCrossRefGoogle Scholar
  17. 17.
    Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114(3):485–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Homey B, Gerber PA, Wollenberg A, Dirschka T, Hassel JC, Bolke E, et al. Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. J Dtsch Dermatol Ges. 2012;10(8):559–63.PubMedGoogle Scholar
  19. 19.
    von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301–6.CrossRefGoogle Scholar
  20. 20.
    Lin NU, Kasparian E, Morganstern DE, Beard C. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap. J Clin Oncol. 2009;27(34):e218–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528–38.PubMedCrossRefGoogle Scholar
  22. 22.
    Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Belloni B, Schonewolf N, Rozati S, Goldinger SM, Dummer R. Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy. 2012;97:191–202.PubMedCrossRefGoogle Scholar
  24. 24.
    Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314–22.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2012;27(1):11–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 2012;6:53–66.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sibaud V, Delord JP, Chevreau C, Gangloff D, Garrido-Stowhas I. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Ann Chir Plast Esthet. 2012;57(2):106–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Wenk KS, Pichard DC, Nasabzadeh T, Jang S, Venna SS. Vemurafenib-induced DRESS. JAMA Dermatol. 2013;149(10):1242–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Gelot P, Dutartre H, Khammari A, Boisrobert A, Schmitt C, Deybach JC, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22(4):297–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480–1.PubMedCrossRefGoogle Scholar
  33. 33.
    Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134(5):1351–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375–83.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Cohen PR, Bedikian AY, Kim KB. Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol. 2013;6(5):27–37.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, et al. RASopathic skin eruptions during vemurafenib therapy. PLoS One. 2013;8(3):e58721.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Schad K, BaumannConzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res. 2010;16(3):1058–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol. 2011;91(5):584–5.PubMedGoogle Scholar
  41. 41.
    Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008;19(8):1387–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59(4):526–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27(27):4536–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Robert C, Sibaud V. Manifestations cutanées des thérapies ciblées anticancéreuses. 1e ed. Toulouse: Privat; 2010.Google Scholar
  45. 45.
    Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118(20):5078–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47(9):1287–98.PubMedCrossRefGoogle Scholar
  47. 47.
    Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.PubMedCrossRefGoogle Scholar
  48. 48.
    Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther. 2005;77(1):76–89.PubMedCrossRefGoogle Scholar
  49. 49.
    O’Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26(10):1588–95.PubMedCrossRefGoogle Scholar
  50. 50.
    Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26(10):1603–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Peuvrel L, Quereux G, Brocard A, Saint-Jean M, Dreno B. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology. 2012;224(3):204–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12):2336–47.PubMedCrossRefGoogle Scholar
  53. 53.
    Ulrich J, Hartmann JT, Dorr W, Ugurel S. Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges. 2008;6(11):959–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24(4):386–95.PubMedCrossRefGoogle Scholar
  55. 55.
    Sendagorta E, Herranz P, Feito M, Ramirez P, Feltes R, Floristan U, et al. Lichenoid drug eruption related to imatinib: report of a new case and review of the literature. Clin Exp Dermatol. 2009;34(7):e315–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Zhang M, Hassan KM, Musiek A, Rosman IS. Ponatinib-induced neutrophilic panniculitis. J Cutan Pathol. 2014;41(7):597–601.PubMedCrossRefGoogle Scholar
  57. 57.
    Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol. 2012;6(2):290–5.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.PubMedCrossRefGoogle Scholar
  59. 59.
    Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs. 2012;30(5):2066–79.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs. 2013;31(4):1078–86.PubMedCrossRefGoogle Scholar
  62. 62.
    Ishak RS, Aad SA, Kyei A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. Crit Rev Oncol Hematol. 2014;90(2):152–64.PubMedCrossRefGoogle Scholar
  63. 63.
    De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014;22(3):837–46.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–97.PubMedCrossRefGoogle Scholar
  65. 65.
    McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396–400.PubMedCrossRefGoogle Scholar
  66. 66.
    Sibaud V, Dalenc F, Chevreau C, Roche H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16(10):1469–78.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291–302.PubMedCrossRefGoogle Scholar
  68. 68.
    Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2010;78(1):24–32.PubMedCrossRefGoogle Scholar
  69. 69.
    Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, et al. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs. 2012;16(2):172–84.PubMedCrossRefGoogle Scholar
  70. 70.
    Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9(1):13–23.PubMedCrossRefGoogle Scholar
  72. 72.
    Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61(2):360–1.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol. 2013;18(6):1060–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Hubiche T, Valenza B, Chevreau C, Fricain JC, Del Giudice P, Sibaud V. Geographic tongue induced by angiogenesis inhibitors. Oncologist. 2013;18(4):e16–7.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144(6):820–2.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.PubMedCrossRefGoogle Scholar
  78. 78.
    Sibaud V, Garrido-Stowhas I, Cottura E, Chevreau C. Dermatologic side effects induced by new angiogenesis inhibitors. Bull Cancer. 2011;98(10):1221–9.PubMedGoogle Scholar
  79. 79.
    Billemont B, Barete S, Rixe O. Scrotal cutaneous side effects of sunitinib. N Engl J Med. 2008;359(9):975–6 (discussion 6).PubMedCrossRefGoogle Scholar
  80. 80.
    Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013;24(11):2922–6.PubMedCrossRefGoogle Scholar
  84. 84.
    LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Dermato CancerologyNantes University Hospital, INSERM U892-CNRS U6299, CIC Biothérapie INSERM 0503NantesFrance

Personalised recommendations